Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

The alert urged Americans to seek medical help in the event they suffered any "unusual, unexplained physical symptoms or events, auditory or sensory phenomena, or other health concerns." The alert comes as a U.S. medical team is screening more Americans who work at the Guangzhou consulate. A previous case in Guangzhou, disclosed last month, prompted the tests. The incidents have raised fears the unexplained issues that started in Cuba in 2016 have expanded to other countries. China says it has uncovered no information that could point to a cause. The most recent evacuations followed medical testing that revealed they might have been affected. State Department spokeswoman Heather Nauert said "a number of individuals" had been brought to the U.S. but didn't say how many were affected or evacuated. Friday's alert called for people to be attentive of symptoms including "dizziness, headaches, tinnitus, fatigue, cognitive issues, visual problems, ear complaints and hearing loss, and difficulty sleeping." It urged them "not to attempt to locate the source of any unidentified auditory sensation. Instead, move to a different location." The U.S. government has deemed the Cuba incidents "specific attacks" on American workers but hasn't publicly identified a cause or culprit. Most of the incidents were accompanied by bizarre, unexplained sounds that initially led U.S. investigators to suspect a sonic attack. Asked about the latest incidents, Chinese Foreign Ministry spokeswoman Hua Chunying said Thursday that the U.S. had not formally raised the matter with Beijing. "If the U.S. makes formal contact with us, China will continue necessary investigations in an earnest and responsible manner and maintain close communication and cooperation with the U.S.," Hua said at a regularly scheduled news conference. China earlier said it had looked into the case announced last month but came up with no clues about the cause of the symptoms. A U.S. official, who wasn't authorized to discuss the situation publicly and requested anonymity, said the evacuated American government workers were being brought from China for testing to the University of Pennsylvania. That's where doctors have been treating and studying patients previously evacuated from the U.S. Embassy in Havana. The preliminary findings of the medical reports on the 24 personnel affected in Cuba showed they had sensory and memory problems similar to the brain dysfunction seen with concussions. The Penn team said the patients from Cuba experienced persistent disability though rehabilitation therapy customized for them seemed to help. Canada in April also ordered families of diplomatic staff in Cuba to return home after mysterious health symptoms were detected in 10 Canadians stationed on the island. Canada said the 10 continued to show unexplained brain symptoms and that "medical information raised concerns for a new type of a possible acquired brain injury." In testimony before the Senate Foreign Relations Committee last month about the first case in China, U.S. Secretary of State Mike Pompeo said China had "said all the right things and have demonstrated their willingness to help us identify the vector which led to this medical incident." The China incidents affect one of the most important of the seven U.S. diplomatic outposts in the country. The Guangzhou consulate opened months after the establishment of diplomatic relations between Beijing and Washington in 1979 and moved to its new purpose-built facility in 2013. It serves four southern provinces with a combined population of more than 204 million and processes more than 1 million visa applications of all types annually. It is also the only U.S. diplomatic installation in China authorized to process immigrant visas and handle adoptions. People working in The Canton Place complex, a few kilometers (miles) from the consulate, said Thursday they were just hearing about the incidents, reflecting a lack of coverage in China's entirely state-controlled media. Aled Williams, a British teacher at a kindergarten said Thursday that the reports sounded "sci-fi-ish." "Hard to get my head around how it works," he said. "Better watch myself." Linda Chen, who runs a coffee shop in the area, said she was mystified as to why only certain people seemed to have been affected in an area known for its comfort and safety. "For me I feel it's very strange. But I don't feel that there's something to be very afraid of because it's probably a very special case," Chen said. ___ Associated Press writer Josh Lederman in Washington, D.C. contributed to this report.
US Embassy in China sends new alert for mystery health issue.

Jennifer Hope Mikesell, of Northwood, is charged with ongoing criminal conduct, fraudulent practices and forgery. Her attorney didn't immediately return a call Tuesday from The Associated Press. Authorities said more charges might be filed later. The Worth County Sheriff's Office said the 43-year-old Mikesell had told people she was diagnosed with cancer and was receiving cancer treatments at Mayo Clinic Health System in Rochester, Minnesota. Iowa court records say Mayo had no record of Mikesell being diagnosed or treated there. Mikesell received multiple donations of money, food and other supplies, as well as a bedroom makeover from My Happy Haven, the court records say. In a media interview about the makeover, Mikesell said she been fighting liposarcoma since 2016. She also said it had spread to her heart and brain. "You do so much to try to do what you can with the energy you have," Mikesell told KIMT-TV in October. "I have five kids. You still have to try to cook, you still have to make it to their activities. When you come home, you have no energy left. You're done."
Woman accused of faking cancer to reap donations.

The release does not mention cost or whether it's covered by private insurance or Medicare, and in this case, it's a pretty big omission. This may be an enormously expensive treatment for patients and it's why we have a cost criterion in our reviews. The hopeful psoriasis patient who sees this release without a cost discussion might already have their hand on the phone to call their dermatologist. Here's a very rough estimate of what that patient might face in terms of cost: Based on a conservative wholesale price of roughly $4,000 per 80mg injection and following the recommendation (found on the package insert) of twoinjections every two weeks for 12 weeks, followed by monthly injections, we calculated $48,000 for the first 12 weeks plus $36,000 for the following 9 months or $84,000 total. The release stated that by week 12,"76.4 to 81.8 percent of patients had their psoriasis classified as "clear" or "minimal" compared to 3.2% of patients on the placebo. By the 60th week, 68.7 to 78.3 percent of patients had maintained their improvement." We also wanted more detail on the measured strength of the response for each patient. For example, what constitutes "minimal"? The release adequately addresses harms and notes that long-term side effects are unknown with this sentence: "Adverse events associated with ixekizumab included slightly higher rates of neutropenia (low white blood cell count), yeast infection and inflammatory bowel disease compared to the placebo. The safety of therapy longer than 60 weeks will need to be monitored in the future." The release clearly and thoroughly describes the three phase 3 international trials at 21 sites, that they enrolled a large number of patients, and that they were randomized and controlled. There was no disease mongering. The release describes what psoriasis is and its prevalence, and explains that these trials were for moderate to severe psoriasis which covers at least 10 percent of the body. The release is very transparent in stating that the drug manufacturer paid for the research and that the lead researcher is a paid consultant to Eli Lilly. The release did not compare the many different ways that patients treat psoriasis, some with topical agents and some with oral steroids or other medications. The release states that the drug has been approved by the FDA following the completion of the trials. This is a strong indication that the drug is or soon will be available. The release should have noted that the drug is already being marketed under the brand name Taltz. The release makes an understated claim to novelty with this quote from the lead researcher: "Ten years ago, we thought complete clearance of this disease was impossible. It wasn't something we would even try to do. Now with this drug, we're obtaining response levels higher than ever seen before." There was no unjustifiable language in the release.
New drug clears psoriasis in clinical trials